FY2025 · ended Dec 31, 2025 · Revenue $1.73B, +114.5% YoY · Filed Feb 19, 2026
PTC Therapeutics, Inc. (PTCT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.7 billion and net income of $682.6 million. Free cash flow was $702.3 million. As of Sep 30, 2026 it held $2.1 billion in cash and investments and $925.7 million in total debt.
Revenue (TTM)
$1.16B
-35.1% vs year-ago TTM
Net income (TTM)
$-105.97M
-114.1% vs year-ago TTM
Operating cash flow (TTM)
$10.49M
-98.5% vs year-ago TTM
Free cash flow (TTM)
$2.07M
-99.7% vs year-ago TTM
EPS (TTM)
$-1.15
-112.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
82.77M
+5.0% vs prior year
Net cash
$1.20B
as of Sep 30, 2026
Operating margin
12.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PTCT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Warren, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1070081
- Former names
- PTC THERAPEUTICS INC (until Oct 12, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.7B | $806.8M | $937.8M | $698.8M | $538.6M |
| Operating income | $866.9M | -$302.6M | -$439.5M | -$447.4M | -$374.4M |
| Net income | $682.6M | -$363.3M | -$626.6M | -$559.0M | -$523.9M |
| Diluted EPS | $7.78 | -$4.73 | -$8.37 | -$7.79 | -$7.43 |
| Operating cash flow | $711.2M | -$107.7M | -$158.4M | -$356.7M | -$251.3M |
| Free cash flow | $702.3M | -$114.2M | -$186.9M | -$388.7M | -$279.5M |
| Total assets | $2.9B | $1.7B | $1.9B | $1.7B | $1.9B |
| Total liabilities | $3.1B | $2.8B | $2.7B | $2.1B | $1.9B |
| Stockholders' equity | -$205.3M | -$1.1B | -$818.6M | -$347.1M | $1.4M |
| Cash and investments | $1.9B | $1.1B | $876.7M | $410.7M | $773.4M |
| Total debt | $398.7M | $389.3M | $415.0M | $703.6M | $535.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 21, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 28, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 13, 2026 | Aug 12, 2026 |
All 1000 PTC Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.